Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Snigmin B is a multi-ingredient nutritional supplement developed and marketed by SNIG Pharma. It is formulated as an oral tablet containing a combination of antioxidants, vitamins, and minerals, specifically alpha lipoic acid, benfotiamine, carbonyl iron, elemental chromium, folic acid, methylcobalamin, myo-inositol, and pyridoxine. This combination is primarily used to manage nutritional deficiencies and provide metabolic support, particularly in patients with diabetic neuropathy. The components work synergistically to improve nerve conduction, reduce oxidative stress, and support healthy glucose metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Snigmin B.